Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of “Moderate Buy” from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $40.8182.

A number of brokerages have issued reports on CAPR. Maxim Group upped their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. B. Riley restated a “buy” rating and set a $50.00 price target (up previously from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Roth Capital raised their price target on Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Finally, Oppenheimer increased their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research note on Monday, December 8th.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. Goldman Sachs Group Inc. boosted its stake in shares of Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after purchasing an additional 116,373 shares during the period. KLP Kapitalforvaltning AS increased its stake in Capricor Therapeutics by 65.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after buying an additional 4,300 shares during the period. Geode Capital Management LLC lifted its holdings in Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after buying an additional 61,701 shares in the last quarter. HBK Sorce Advisory LLC boosted its position in Capricor Therapeutics by 33.7% in the 3rd quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock valued at $1,141,000 after buying an additional 42,951 shares during the period. Finally, Woodline Partners LP grew its stake in Capricor Therapeutics by 15.8% in the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock worth $6,921,000 after acquiring an additional 99,384 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 6.7%

CAPR stock opened at $23.84 on Monday. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The firm has a market capitalization of $1.09 billion, a P/E ratio of -13.24 and a beta of 0.22. The company has a fifty day simple moving average of $17.95 and a two-hundred day simple moving average of $11.05.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). As a group, analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.